MSB

10.4%

$1.49 mesoblast limited

MSB All-time low Party Thread, page-25

First 25 Last

Share
Profile

Follow
Bazsa

3,960 Posts.

1357

30/06/22

07:38

Post #: 62285682
Share

Originally posted by DocMcstuffins: ↑

The lottery is also binary, you either win or you don't.

Also, consider that approval isn't everything. It is just another milestone towards getting cash flow.

Even if MSB gets approval, this isn't a guarantee the product will be a success. There will be ongoing analysis of the data (phase 4 trials) so we had better hope we do have robust results - many products get pulled after approval.

It's a very expensive product, so it also had better be superior to current standards of care - many of which it isn't being trialled against.

For example, it showed a modest reduction in pain score (but no functional improvement) compared to saline for CBP. But what about against steroid injections, which are 1/100th of the price.

Even if we think it's superior to steroids, we want patients and doctors to be convinced enough to fork out the money.

Also keep in mind, revenue growth from existing products in approved countries is slowing already - this is something to keep an eye on, and no one here has offered a reason why this is.

Either the market isn't as big as we thought, and it's already becoming saturated, or the product isn't working in the real world as we had hoped.

This is one of the major issues with designing trials to succeed, rather for them to hold validity.

Using saline as a control instead of HA - sure, FDA says it's good enough to get approval. But will the customers be convinced (who are likely know how to interpret studies)?

So approval isn't the end game. That's just the beginning. Those "triple digit returns" on approval simply bring you back to prices you were at last year.

Then the real test comes - whether people want the product, whether MSB can expand production (notoriously difficult for this sort of therapy), whether the product stands up against analysis in the real world.

GLTAH. But things aren't really as binary as you think

Expand

Are you OK Doc? You do realise you are on the MSB board. This is not PNV

MSB Price at posting: 64.5¢ Sentiment: Buy Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BUX

Buxton projects new graphite province discovery at WA Narryer play

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 372 more messages in this thread...

First 25 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.49		Change 0.140(10.4%)		Mkt cap ! $1.701B

Open	High	Low	Value	Volume
$1.37	$1.54	$1.37	$23.10M	15.82M

Buyers (Bids)

No.	Vol.	Price($)
3	24758	$1.49

Sellers (Offers)

Price($)	Vol.	No.
$1.49	73626	3

View Market Depth

No.	Vol.	Price($)
1	10033	1.485
4	53700	1.480
1	770	1.475
3	62048	1.460
1	50000	1.455

Price($)	Vol.	No.
1.490	21995	1
1.505	24000	1
1.510	13666	2
1.515	99798	1
1.520	27250	3

Last trade - 16.10pm 04/10/2024 (20 minute delay)

MSB (ASX) Chart

MSB All-time low Party Thread, page-25

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Buxton projects new graphite province discovery at WA Narryer play

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MSB All-time low Party Thread, page-25

Top Stories

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Buxton projects new graphite province discovery at WA Narryer play

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News